Efficacy of troxerutin on streptozotocin-induced rat model in the early stage of diabetic retinopathy

Arzneimittel-Forschung/Drug Research

Volumn 55, Issue 10, 2005, Pages 573-580

  Chung, Han Kook ^a   Choi, Seul Min ^a   Ahn, Byoung Ok ^a   Kwak, Hyun Hee ^a   Kim, Jeong Hoon ^a   Kim, Won Bae ^a  

^a Dong A Pharmaceutical Company   (South Korea)

Author keywords

Calcium dobesilate; CAS 20123 80 2; CAS 7085 55 4; Diabetic retinopathy; Troxerutin; Vaccinium myrtillus; Vascular endothelial growth factor

Indexed keywords

ANTIOXIDANT; APYRASE; BETA ACTIN; DOBESILATE CALCIUM; GLUCOSE; MESSENGER RNA; STREPTOZOCIN; TROXERUTIN; VACCINIUM MYRTILLUS EXTRACT; VASCULOTROPIN;

ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE FUNDUS; EYE PHOTOGRAPHY; GLUCOSE BLOOD LEVEL; HISTOCHEMISTRY; IMAGE ANALYSIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; RAT; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; TISSUE HOMOGENATE;

EID: 27544481345     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296907     Document Type: Article

References (33)

1. Nathan, D. M., The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Ann. Int. Med. 124, 86 (1996)
2. Hammes, H. P., Lin J., Renner O. et al., Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51, 3107 (2002)
3. Chihara, E., Matsuoka, T., Ogura, Y. et al., Retinal nerve fiber layer defect as an early manifestation of diabetic retinopathy. Ophthalmology 100, 1147 (1993)
4. Schellini, S. A., Gregorio, E. A., Spadella, C. T. et al., Mullar cells and diabetic retinopathy. Braz. J. Med. Biol. Res. 28, 977 (1995)
5. Klein, R., Klein, B. E. K., Moss, S. E., Epidemiology of proliferative diabetic retinopathy. Diabetes Care 15, 1875 (1992)
6. Porta, M., Bandello, F., Diabetic retinopathy. Diabetologia 45, 1617 (2002)
7. Davis, M. D., Norton, E. W. D., Myers, F. L., The Airlie House classification of diabetic retinopathy. In: Goldberg, M. F., Fine, S. L. (eds.), Symposium on the treatment of diabetic retinopathy. P.H.S. publication No. 1890, Washington, DC (1969)
8. Aiello, L. P., Avery, R. L., Arrigg, P. G. et al., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480 (1994)
9. Adamis, A. P., Miller, J. W., Bernal, M. T. et al., Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118, 445 (1994)
10. Valerie, A. A., Er-Ning, S., Dao-Yi, Y. et al., Diabetic retinopathy: early functional changes. Clin. Exp. Pharmacol. Physiol. 24, 785 (1997)
11. Wadworth, A. N., Faulds, D., Hydroxyethylrutosides: a review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs 44, 1013 (1992)
12. Janssens, D., Michiels, C., Arnould, T. et al., Effects of hydroxyethylrutosides on hypoxia-induced activation of human endothelial cells in vitro. Br. J. Pharmacol. 118, 599 (1996)
13. MacLennan, W. J., Wilson, J., Rattenhuber, V. et al., Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology 40, 45 (1994)
14. Moses, M., Ranacher, G., Wilmot, T. J. et al., A double-blind clinical trial of hydroxyethylrutosides in Meniere's disease. J. Laryngol. Otol. 98, 265 (1984)
15. Poynard, T., Valterio, C., Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa 23, 244 (1994)
16. Bkisseau, M. R., Taccoen, A., Garreau, C. et al., Fibrinolysis and hemorheology in chronic venous insufficiency: a double blind study of troxerutin efficiency. J. Cardiovasc. Surg. 36, 369 (1995)
17. Glacet-Bernard, A., Coscas, G., Chabanel, A. et al., A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am. J. Ophthalmol. 118, 421 (1994)
18. Salvayre, R., Braquet, P., Perruchot, T. et al. (eds.), Flavonoids and Bioflavonoids, pp. 437-442, Elsevier, Amsterdam-Oxford etc. (1982)
19. Kuhnau, J., The flavonoids. A class of semi-essential food components. Their role in human nutrition. Wld. Rev. Nutr. Diet 24, 117 (1976)
20. Harvsteen, B., Flavonoids, a class of natural products of high pharmacological potency. Biochem. Pharmacol. 32, 1141 (1983)
21. Gabor, M., Pharmacologic effects of flavonoids on blood vessels. Angiologica 9, 355 (1972)
22. Mian, E., Curri, S. B., Lietti, A. et al., Anthocyanosides and the walls of the microvessels: further aspects of the mechanism of action of their protective effect in syndromes due to abnormal capillary fragility. Minerva Med. 68, 3565 (1977)
23. Lietti, A., Cristoni, A., Picci, M., Studies on Vaccinium myrtillus anthocyanosides. I. Vasoprotective and anti-inflammatory activity. Arzneim.-Forsch./Drug Res. 26, 829 (1976)
24. Colantuoni, A., Bertuglia, S., Magistretti, M. J. et al., Effects of Vaccinium myrtillus anthocyanosides on arterial vasomotion. Arzneim.-Forsch./ Drug Res. 41, 905 (1991)
25. Berthet, P., Farine, J. C., Barras, J. P., Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy. Int. J. Clin. Pract. 53, 631 (1999)
26. Brunet, J., Farine, J. C., Garay, R. P. et al., Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat. Eur. J. Pharmacol. 358, 213 (1998)
27. Noriaki, K., Satomi, Y., Takeshi, S. et al., Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J. Diabetes Complications 17, 374 (2003)
28. Lutty, G. A., McLeod, D. S., A new technique for visualization of human retinal vasculature. Arch. Ophthalmol. 110, 267 (1992)
29. Wilkes, S. R. Current therapy of diabetic retinopathy: laser and vitreoretinal surgery. J. Natl. Med. Assoc. 85, 841 (1993)
30. Folkman, J., Haudenschild, C., Angiogenesis in vitro. Nature 288, 551 (1980)
31. Ferrara, N., Houck, K. A., Jakeman, L. B. et al., The vascular endothelial growth factor family of polypeptides. J. Cell. Biochem. 47, 211 (1991)
32. Murata, T., Ishibashi, T., Khalil, A. et al., Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessel. Ophthalmic Res. 27, 48 (1995)
33. Kilic, F., Bhardwaj, R., Trevithick, J. R., Modelling cortical cataractogenesis. XVIII. In vitro diabetic cataract reduction by venoruton. A flavonoid which prevents lens opacification. Acta Ophthalmol. Scand. 74, 372 (1996)